Last update July 14, 2023
Rotigotine is a non-selective non-ergot dopaminergic D2 agonist used for the treatment of Parkinson's disease and restless legs syndrome. It has actions similar to those of bromocriptine. Administration in the form of transdermal patches every 24 hours.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (very large volume of distribution and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.
Being a dopamine agonist, it is very likely to decrease prolactin secretion. Milk production, once lactation is established, is not so much dependent on prolactin as on the frequency of breastfeeding or milk expression. (Messinis 1985)
If it is administered during lactation, it is advisable not to take it during the first postpartum month and to monitor milk production.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM